Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Psyence BioMed to advance development of ibogaine after Trump announcement
Psyence BioMed said it intends to support development of ibogaine after President Trump signaled progress on regulatory steps and research funding. CEO Jody Aufrichtig and CFO Warwick Corden‑Lloyd are meeting with stakeholders in Texas to discuss clinical, regulatory and policy opportunities. The company, via PsyLabs, has access to GMP‑compliant manufacturing and stocks of ibogaine hydrochloride, but stressed that ibogaine remains controlled in the US and no clinical trials for the planned products have yet been conducted. » Plus sur de.investing.com
Psyence Biomedical reports quarterly loss of $0.51 per share
Psyence Biomedical released the numbers for the quarter ended 30 September 2025 at the investor conference on 20 November 2025 and reported an EPS of -$0.51. By comparison, the company had earned $4.14 per share in the same period a year earlier. » Plus sur finanzen.net
Données financières de l'entreprise
| (EUR) | sept. 2025 | |
|---|---|---|
| Chiffre d'affaires | 0,00 | - |
| Bénéfice brut | −1,13k | - |
| Bénéfice net | −641,87k | - |
| EBITDA | −638,39k | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 70,99k€ |
Nombre d'actions | 19,02k |
Plus haut/bas sur 52 semaines | 185,70€ - 1,65€ |
| Dividendes | Non |
Bêta | 1,67 |
Ratio P/E | 0,00 |
Ratio PEG | 0,00 |
Ratio P/B | 0,00 |
Ratio P/S | 0,00 |
Profil de l'entreprise
| Nom | PSYENCE BIOMEDICAL LTD. |
| PDG | Jody Aufrichtig |
| Employés | 12 |
Découvrir des actifs
Les actionnaires de PSYENCE BIOMEDICAL LTD. investissent également dans les actifs suivants
